CD274 and cancer: In other cancer types, several criteria are used to evaluate whether a patient would benefit from anti-PD-1/PD-L1 therapy, including PD-L1 expression, tumor mutation burden (TMB), and microsatellite instability (MSI), which detects mismatch repair defects [19,20].